Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin for cholesterol and cognition in schizophrenia
NCT01082588Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2010
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia and hypercholesterolemia comparing Pravastatin with Placebo (2 arms). Primary endpoints: Change in LDL-cholesterol at 12 weeks, Change in C-Reactive Protein at 12 weeks and 5 more. Started Jun 2010; status: completed.
02
Drugs
pravastatin
03
Conditions
schizophreniahypercholesterolemia
Beyond the preview
Go deeper on NCT01082588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01082588.